Xu Xiang, Li Chengqian, Yu Xiaolong, Wang Guoqiang, Guo Yanjun, Ni Huaiwen, Zhao Wenjuan, Wang Yangang, Dong Bingzi
Department of Geriatrics, The Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China.
Front Endocrinol (Lausanne). 2024 Jul 17;15:1382009. doi: 10.3389/fendo.2024.1382009. eCollection 2024.
Lymph node metastasis is the major cause of increased recurrence and death in patients with papillary thyroid carcinoma (PTC). We evaluate the clinicopathologic factors affecting excellent response (ER) in patients with PTC with lymph node metastasis following operation and I ablation therapy.
A total of 423 patients with PTC with lymph node metastasis who underwent thyroidectomy and postoperative I ablation therapy were enrolled. The relationship between clinicopathological factors affecting ER achievement was analyzed.
Multivariate analysis showed that the foci diameter (≤1 cm), unifocal, combination with Hashimoto's thyroiditis (HT), lymph node metastases rate (LR) (≤40%), no postoperative lymph node metastasis, low preablative stimulated thyroglobulin (ps-Tg) level (≤3.87 ng/mL), and the time of I ablation therapy (one time) were positively correlated with the ER achievement [odds ratio (OR): 1.744, 3.114, 3.920, 4.018, 2.074, 9.767, and 49.491, respectively; all < 0.05]. The receiver operating characteristic (ROC) curves showed that the cutoff values of ps-Tg and LR were 4.625 ng/mL and 50.50%, respectively. The AUC of ROC of ps-Tg and LR for predicting ER achievement was 0.821 and 0.746, respectively. The Tg and the cumulative risk of non-ER elevated with the increase of LR, especially for the high-level ps-Tg (>4.625 ng/mL) group.
The foci diameter and number, combination with HT, LR, and ps-Tg level are independent factors for ER. Ps-Tg level and LR are valid predictive factors for the efficacy of I therapy in patients with PTC. The predictive value of the cumulative risk of non-ER can be improved by the combination of ps-Tg and LR.
淋巴结转移是甲状腺乳头状癌(PTC)患者复发和死亡增加的主要原因。我们评估了影响PTC伴淋巴结转移患者术后行碘消融治疗后获得良好反应(ER)的临床病理因素。
共纳入423例接受甲状腺切除术和术后碘消融治疗的PTC伴淋巴结转移患者。分析影响ER达成的临床病理因素之间的关系。
多因素分析显示,病灶直径(≤1 cm)、单灶、合并桥本甲状腺炎(HT)、淋巴结转移率(LR)(≤40%)、无术后淋巴结转移、消融前刺激甲状腺球蛋白(ps-Tg)水平低(≤3.87 ng/mL)以及碘消融治疗次数(1次)与ER达成呈正相关[比值比(OR)分别为1.744、3.114、3.920、4.018、2.074、9.767和49.491;均P<0.05]。受试者工作特征(ROC)曲线显示,ps-Tg和LR的截断值分别为4.625 ng/mL和50.50%。ps-Tg和LR预测ER达成的ROC曲线下面积(AUC)分别为0.821和0.746。随着LR的增加,Tg及非ER累积风险升高,尤其是ps-Tg高水平(>4.625 ng/mL)组。
病灶直径和数量、合并HT、LR及ps-Tg水平是ER的独立影响因素。ps-Tg水平和LR是PTC患者碘治疗疗效的有效预测因素。联合ps-Tg和LR可提高非ER累积风险的预测价值。